IP Library Granted Patent US 9,617,513
Granted Patent B2
US 9,617,513 · App. 11/029,763 · Granted Apr 11, 2017

Pluripotent embryonic-like stem cells, compositions, methods and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,617,513
App. No.
11/029,763
Granted
Apr 11, 2017
Kind
B2
Abstract

The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.

Claims (5)

1. A method of providing a host with isolated cells derived from postnatal human tissues, the method comprising administering into the host the isolated cells, wherein the isolated cells express SSEA4, do not express CD34, have a normal karyotype, do not form tumors in the host, are capable of self-renewal, and are capable of differentiation to cells of endodermal, ectodermal and mesodermal lineages, said isolated cells having been produced by expanding, in culture, a cultured cell clone from a postnatal human tissue.

2. The method of claim 1 wherein the isolated cells are administered in combination with one or more proliferation factors or lineage commitment factors.

3. The method of claim 1 wherein the expansion is greater than 50 cell doublings.

4. The method of claim 1 wherein the expansion comprises cell doublings of between 12 and 47.

5. The method of claim 1 wherein the isolated cells have been passaged and cryopreserved after passage prior to introduction to the host.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2009
From: CYBIOS LLC
To: ABT HOLDING COMPANY
Reel/Frame 023693/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2009
From: YOUNG, HENRY E.; LUCAS, PAUL A.
To: MORPHOGEN PHARMACEUTICALS, INC.
Reel/Frame 022104/0354 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 14, 2009
From: MORPHOGEN PHARMACEUTICALS, INC.
To: CYB MORPH L.L.C.
Reel/Frame 022104/0594 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 14, 2009
From: CYB MORPH L.L.C.
To: CYBIOS L.L.C.
Reel/Frame 022104/0781 →